Evolution and surveillance of multiple sclerosis;Evolution et surveillance de la sclerose en plaques

Revue du Praticien

Volumn 49, Issue 17, 1999, Pages 1866-1871

  Edan, Gilles ^a   Coustans, Marc ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISABILITY; DISEASE COURSE; HUMAN; LONGEVITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SYMPTOMATOLOGY;

CENTRAL NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS;

EID: 0033231198     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Weinshenker G, Bass B, Rice GPA et al. The natural history of multiple sclerosis : a geographical based study I. Clinical course and disability. Brain 1989; 112 : 133-46.
2. Weinshenker BG, Bass B, Rice GPA et al. The natural history of multiple sclerosis : a geographically based study 2. Predictive value of the early clinical course. Brain 1989; 112 : 1419-28.
3. Lublin FD, Reingold SC, for the national multiple sclerosis society (USA) Advisory committee on clinicac trials of new agents in multiple sclerosis. Defining the clinical course of multiple sclerosis : results of an international survey. Neurology 1996; 46 : 907-11.
4. Edan G, Sabouraud O. Les formes bénignes de sclérose en plaques. Rev Prat 1991; 41 (20) : 1904-7.
5. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis : MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994; 57 : 1070-2.
6. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103 : 281-300.
7. Runmarker B, Andersen O. Pronostic factors in a multiple slerosis Incidence cohort with twenty five years of follow-up. Brain 1993; 116 : 117-34.
8. Cottrell DA, Kremenchutzky M, Rice GPA et al. The natural history of multiple sclerosis : a geographically based study 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122 : 625-39.
9. Kantarci O, Siva A, Eraksoy M et al. Survival and predictors of disability in Turkish MS patients. Neurology 1998; 51 : 765-72.
10. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in danish patients with multiple sclerosis : result from the danish multiple sclerosis registry. J Neurol Neurosurg Psychiatry 1998; 65 : 56-9.
11. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis : result from a epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987; 50 : 523-31.
12. Phadke JG. Clinical aspect of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990; 113 : 1597-628.
13. Kurtzke JF. Rating neurological impairment in MS : an expanded disability status scale (EDSS). Neurology 1983; 33 : 1444-52.
14. Rudlck R, Artel J, Confavreux C et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. Ann Neurol 1997; 42 : 379-82.
15. Morrisey SP, Miller DH, Kendall BE et al. The signifiance of brain magnetic resonance imaging abnormalities at presentation with clinically Isolated syndromes suggestive of multiple sclerosis. Brain 1993 ; 116 : 135-46.
16. Cole SR, Beck RW, Moke PS, Kaufman DI, Tournelotte WW for the optic neuritis study group. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Neurology 1998; 51 : 885-7.
17. O'Riordan JI, Thompson AJ, Kingsley DPE et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS a 10 year follow - up. Brain 1998; 121 : 495-503.
18. Sailer M, O'Riordan JI, Thompson AJ et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52 : 599-606.
19. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121 : 3-24.
20. Edan G, Miller D, Clanet M. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis : a randomized multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62 : 112-8.
21. Filippi M, Iannucci G, Tortorella C et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999; 52 : 588-94.
22. Berry I, Ranjeva JP, Manelfe C, Clanet M. Visualisation de l'IRM des lésions de SEP. Rev Neurol 1998; 154 : 607-17.